Response Evaluation in Oncology Trials

In this eBook, we review the history of response evaluation in oncology trials as it has changed alongside technology and share our view of its future.

Learn More >

Approaching a Post-Antibiotic Era: Trends in Antibiotic Research

This eBook provides an overview of the challenges we continue to face with antibiotic and bacterial resistance.

Learn More >

Predictive Resupply in Clinical Research: How to Cut Costs and Ensure Adherence to Study Protocols

This whitepaper explains the shortcomings of the floor-and-ceiling drug resupply method. We outline a 5-step algorithm for your clinical trial to cut costs and adhere to protocols.

Learn More >

Reconsidering India as a Clinical Trial Location

India's regulatory environment has made it difficult to conduct clinical research. This whitepaper explores how policies have evolved in recent years.

Learn More >

Clinical Trials in Canada: A Separate but Familiar Venue

The United States is a common site for launching Phase I-III clinical trials, but Canada offers similar prospects for trial success and should not be overlooked.

Learn More >

Clinical Trials in Latin America: A Region of Diversity, A World of Opportunity

Latin America, which boasts easy access to a diverse patient population, is more conducive to conducting clinical trials than ever before. Find out more in these pages.

Learn More >

Clinical Trials in Ukraine: Untapped Potential & Proven Experience

Despite political unrest in a small section of the country, clinical trials are thriving in Europe’s second largest country. Read our whitepaper to learn more.

Learn More >

Conducting Clinical Trials in Turkey: A Resource Guide for Sponsors

Turkey is an up-and-coming location for savvy clinical trial managers. Read on for a comprehensive guide to the country’s dynamic research environment.

Learn More >

Clinical Trials in Belarus: A Primer for Sponsors

Belarus is a hidden gem for clinical trial managers. In these pages, you will learn about its high enrollment rates, favorable cost structure, and more.

Learn More >

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Biopharmaceutical companies are turning toward emerging markets to reduce clinical trial costs and timelines. Here, we weigh the benefits and drawbacks.

Learn More >

Clinical Trials in Russia:The Promise and the Approach

Thanks to its large population and centralized health care system, Russia has become an excellent choice for clinical trials. Our whitepaper details why.

Learn More >

Passing the Baton: The Do's and Don'ts of Study Transfer

Sponsors don’t expect to transfer responsibility of a trial to a new CRO—but it can be necessary. Here, we show what a successful transfer looks like.

Learn More >